JLJens Laigaard

Jens Laigaard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jens Laigaard has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Implementation of high-dose glucocorticoids and opioid consumption in the first 24 hours after elective hip and knee arthroplasty: a natural experiment study of 47,317 procedures in Eastern Denmark

    by Jens Laigaard, Marcus Ø Møller, Markus H Olsen, Søren Overgaard, Ole Mathiesen, Anders Ph Karlsen

    Background: In Denmark, high-dose perioperative glucocorticoids were implemented stepwise for patients undergoing total hip arthroplasty (THA), total knee arthroplasty (TKA), and unicompartmental knee arthroplasty (UKA). We aimed to estimate the opioid-sparing effect of adding a single high dose of glucocorticoids to the analgesic regimen. Methods: In this prespecified analysis of a multicentre natural experiment using electronic health record data, we included all elective THA, TKA, or UKA procedures performed in Eastern Denmark from 2017-2025, with no exclusion criteria. At each centre, procedures before implementation of high-dose glucocorticoids served as controls, whereas procedures after implementation comprised the intervention group. A high dose was defined as ≥16 mg or 0.2 mg/kg dexamethasone or ≥80 mg methylprednisolone. The primary outcome was the adjusted between-group difference in 0-24h opioid consumption. The minimal important difference was 5 mg IV morphine equivalents. Secondary outcomes were maximum 0-10 numerical rating scale (NRS) pain score, incidence of opioid-related adverse events, hospital length of stay, and days alive and out of hospital at 30 days. Results: We analysed 47,317 procedures performed at nine centres: 13,010 controls and 34,307 in the intervention group. During the study period, five of nine centres implemented high-dose glucocorticoids for THA patients, two of eight for TKA/UKA patients. High-dose glucocorticoids were administered to 6% and 92% of patients before and after implementation, respectively. The implementation was associated with an adjusted mean reduction of 3.8 mg IV morphine equivalents (95% CI 3.3–4.3) and a 0.8-point lower maximum recorded pain score (99% CI 0.7–0.9) in the first 24 hours, with no statistically significant differences in the remaining outcomes. Conclusions: Implementation of high-dose glucocorticoids was associated with only a small drop in opioid consumption, below the minimal important difference. Key Points Summary: Question : What opioid-sparing effects may be expected when adding high-dose glucocorticoids (≥16 mg or 0.2 mg/kg dexamethasone or ≥80 mg methylprednisolone) to the standard analgesic package for patients undergoing total hip and knee arthroplasty? Findings : In Eastern Denmark, the adoption of high-dose glucocorticoids to the existing multimodal analgesic regimen was associated with a slightly lower 0-to-24 hours in-hospital opioid consumption, according to electronic health record data. Meaning : Clinicians may expect a slightly lower opioid-sparing effect from high-dose glucocorticoids than found in randomised clinical trials.

  • Open Access

    Prognostic Factors for Postoperative Complications. An Aggregate Protocol for 10 Observational Studies From the Danish TRIPLE ‐A Cohort of 1.2 Million Surgeries

    by Anders Peder Højer Karlsen, Asta Prescott, Caroline Folkersen, Jens Laigaard, Atena Saito, Caroline Lando Klammer, Mik Wetterslev, Emil Ipsen Ørskov, Mathilde Fahrendorff, Rebecca Kiær, et al.

    Background: Postoperative complications substantially increase morbidity, mortality and healthcare costs. Understanding prognostic factors is essential for risk stratification, targeted prevention strategies, and development of prediction models. Objectives: To identify prognostic factors for 18 major postoperative complications in 10 studied domains using the Danish TRIPLE‐A database: (1) acute postoperative pain, nausea and vomiting, and need for rescue opioids; (2) persistent opioid use; (3) acute kidney injury; (4) venous thromboembolism; (5) staphylococcal surgical site infection and infections requiring antibiotic treatment; (6) three airway management complications; (7) transfusion requirements; (8) delirium; (9) new‐onset postoperative atrial fibrillation; and (10) readmission, reoperation and unplanned ICU admission. Methods: We will conduct 10 retrospective cohort studies using electronic health record data from 1.2 million surgical procedures performed in the Capital and Zealand Regions of Denmark from 2017 to 2025. Each individual complication will be identified via validated combinations of ICD‐10 codes, medication administration, laboratory values, radiology examinations, and free‐text mining of clinical notes. Candidate prognostic factors will be selected a priori based on literature review and clinical expertise, and will encompass patient demographics, comorbidities, surgical characteristics, anaesthetic management, vital parameters and biomarkers. We will estimate adjusted associations between candidate prognostic factors and complications using multivariable logistic regression with LASSO penalisation to reduce overfitting. Effect estimates will be reported as odds ratios with 95% confidence intervals, and the relative contribution of predictors will be assessed by changes in model discrimination (Δ‐AUC). The approach for surgical procedure, calendar year, and hospital site will be determined for each study (adjustment, stratification, or inclusion as candidate predictors). Conclusion: These studies aim to validate established prognostic factors and identify novel ones for major postoperative complications, providing a foundation for the development of individualised perioperative risk stratification models.

  • Top Cited Papers

    Patient‐Related Predictors of Opioid Use, Pain and Opioid‐Related Adverse Events in the First 24 h After Surgery: A Systematic Review and Meta‐Analysis

    by Caroline Risegaard Folkersen, Ida Houtved Rasmussen, Pernille Bjersand Sunde, Selma Pedersen Kjartansdóttir, Atena Saito, Markus Harboe Olsen, Jens Laigaard, Mathias Maagaard, Ole Mathiesen, Anders Peder Højer Karlsen

    Background and Objectives: Acute postoperative pain is typically managed with titration of opioids, balancing pain intensity and opioid‐related adverse events (ORADEs). Often, the dosing strategy is individualised based on the clinician's intuition or expertise. The influence of broader patient‐related predictors remains insufficiently synthesised. This systematic review aimed to synthesise evidence on associations between patient‐related predictors and opioid use, pain intensity and ORADEs within 24 h after surgery. Databases and Data Treatment: In this systematic review, we searched MEDLINE, Embase and CENTRAL for studies examining associations between patient‐related predictors and opioid use, pain, or ORADEs within 0–24 h postoperatively. We used Quality in Prognosis Studies (QUIPS) for risk of bias and conducted meta‐analyses. Results: We included 39 studies (294,221 patients) investigating 31 patient‐related predictors. Meta‐analyses showed that young age and chronic pain were associated with moderate–severe pain risk and large opioid consumption. Smoking, non‐normal BMI, anxiety and preoperatively opioid use or pain were associated with moderate–severe pain. Female sex and lower ASA‐scores were associated with postoperative nausea and vomiting. No other ORADEs were assessed. All but two studies were high risk of bias. Conclusion: The certainty of evidence was low due to high risk of bias and substantial heterogeneity in designs, populations and exposure/outcome definitions. Within 24 h after surgery, younger age, female sex, lower ASA score, smoking, abnormal BMI, anxiety, chronic pain and chronic opioid use were associated with greater postoperative complexity in terms of increased pain intensity, opioid use, or risk of nausea and vomiting. Significance Statement: This comprehensive review provides important understanding of patient‐related predictors, which can contribute to a more individualised perioperative pain management, including dosing of preventive analgesia at the end of surgery and in adjusting as‐needed opioid doses postoperatively. Prospero‐Identifier: CRD42024559821.


  • Open Access

    Surgical and nonsurgical treatment of hip and knee osteoarthritis: a 2026 perspective

    by Jens Holm Laigaard, Tazio Maleitzke, Søren T Skou, Inger Mechlenburg, Thomas Bandholm, Lise C Berg, Søren Overgaard

  • Open Access

    Real-world Opioid-Sparring Effects of Infiltration between the Popliteal Artery and the Capsule of the Knee (IPACK) in Patients Undergoing Anterior Cruciate Ligament Reconstruction

    by Anders Peder Højer Karlsen, Markus Harboe Olsen, Kristoffer Barfod, Troels Haxholdt Lunn, Martin Bitsch, Sebastian Wiberg, Jens Laigaard

    Introduction: Patients undergoing anterior cruciate ligament (ACL) reconstruction experience substantial postoperative pain, which delays recovery and leads to both immediate and long-term opioid use. In other knee procedures, infiltration between the popliteal artery and the capsule of the posterior knee (IPACK) has demonstrated analgesic and opioid reducing effects. However, the effect in patients undergoing ACL reconstruction has not been investigated. We aimed to investigate the real-world effect of IPACK in patients undergoing ACL reconstruction on immediate postoperative opioid consumption. Participants: In this single-centre difference-in-differences cohort study, all patients who underwent ACL reconstruction surgery at Bispebjerg Hospital, Denmark, from 1 February 2024 to 30 June 2025 are included. The study further includes a similar reference cohort, comprising all patients who underwent trochleaplasty, Elmslie-Trillat, or medial patellofemoral ligament reconstruction during the same period, and at the same hospital. Intervention: The primary exposure is the implementation of IPACK as part of perioperative management for ACL reconstruction on 1 January 2025. The IPACK was performed under ultrasound guidance, immediately before surgery, administering 20 mL of ropivacaine 0.5% between the popliteal artery and the posterior knee capsule. Outcomes: The primary outcome is the cumulative opioid consumption from surgical incision to 2 hours postoperatively. Secondary outcomes include the cumulative opioid consumption from incision to 24 hours postoperatively, the worst reported pain score at 0-24h postoperatively, occurrence of postoperative nausea or vomiting (PONV) 0-24h postoperatively, length of PACU stay, length of hospital stay, and nerve injuries. As an exploratory outcome, carbon dioxide emissions will be investigated. Statistical analysis: The main analysis will be a standard two-way fixed effects DiD regression assessing the changes occurring at the time of implementation of IPACK in the ACL cohort, with adjustment for the underlying time trend. Continuous outcomes are reported as mean difference (95% confidence interval [CI]), and binary outcomes as absolute and relative risks (95% CI).

  • Open Access

    High-dose glucocorticoids, pain, and adverse events. Protocol for an analysis of a natural experiment of patients undergoing hip and knee arthroplasty

    by Jens Laigaard, Marcus Oelgaard Moeller, Soeren Overgaard, Ole Mathiesen, Anders Peder Højer Karlsen

    Introduction: High-dose glucocorticoids are increasingly used in patients undergoing primary total hip arthroplasty (THA), unicompartmental knee arthroplasty (UKA), and total knee arthroplasty (TKA). However, the evidence supporting the use of high-dose glucocorticoids to manage acute postoperative pain is based mainly on randomised controlled trials, which may have limited external clinical validity due to strict exclusion criteria. In Denmark, the treatment was implemented stepwise, comprising a natural experiment. Objective: To examine the real-world effect of a single dose of high-dose glucocorticoids on postoperative opioid consumption and adverse events in patients undergoing THA, UKA, and TKA. Methods: This protocol describes a natural experiment study that will be reported as a target trial emulation, i.e. by attempting to mimic a randomised clinical trial. Inclusion and exclusion criteria: All adults (>18 years) undergoing primary, elective THA, UKA, and TKA in the Capital Region and Region Zealand in Denmark are eligible Intervention: The intended use of a single high dose of glucocorticoids, administered after induction of anaesthesia, as part of the standard treatment. Comparator: No administration of glucocorticoids. Patients in the control arm may have received a lower dose of glucocorticoids for postsurgical nausea and vomiting Assignment of intervention: For each hospital, patients who underwent surgery before the implementation of glucocorticoids serve as controls, while patients operated on after the implementation constitute the treatment arm. Outcomes: The primary outcome is opioid consumption, expressed in morphine equivalent doses (MEQs) in the first 24 hours after surgery. Secondary outcomes are two adverse effect-outcomes: incidence of opioid-related adverse events and days alive and out of hospital at 30 days, and three efficacy-outcomes: length of postoperative observation area-stay, length of hospital stay, and worst 0-24-hour pain intensity score measured. Data collection: This study uses data from the TRIPLE-A project ( www.triplea.dk ), comprising validated electronic health record data. Statistical analyses: The analyses will be based on a pre-defined mixed effects model with hospital as a random effect and adjusted for important presurgical (and thus pre-intervention) variables. A perprotocol population will be analysed as a sensitivity analysis. For the primary outcome, a difference of 5 MEQs between treatment arms is considered clinically important. Knowledge dissemination: The results will be shared at conferences and made publicly available. Registration: https://doi.org/10.1101/2025.11.11.25339982

  • Decision Support Tools for Adjusting Perioperative Opioid Dosing as Individualised Postoperative Pain Management: A Systematic Review

    by Pernille Bjersand Sunde, Ida Houtved Rasmussen, Caroline Folkersen, Atena Saito, Markus Harboe Olsen, Jens Laigaard, Nicholas Papadomanolakis‐Pakis, Troels Haxholdt Lunn, Christian S. Meyhoff, Ole Mathiesen, et al.

    Introduction: Despite decades of efforts to optimize procedure‐specific pain management, up to 60% of surgical patients still experience moderate to severe pain and opioid‐related adverse effects. Current guidelines primarily rely on standardised dosing protocols rather than individual patient characteristics, offering limited support for tailoring opioid therapy to patient‐specific needs. This systematic review aimed to identify studies on decision support tools for adjusting perioperative systemic opioid dosing as individualised postoperative pain management and evaluate their effects on postoperative outcomes. Methods: We searched EMBASE, MEDLINE and Cochrane Library up to August 2025 for studies including adult surgical patients developing, validating or testing decision support tools (prediction models or nociception monitoring systems). Prediction model studies had to include at least two predictors and target the first 24 postoperative hours. Intervention studies had to report pain, opioid use, or opioid‐related adverse events within 24 h. Studies on chronic pain, intraoperative‐only agents (e.g., remifentanil), or unpublished literature were excluded. Risk of bias was assessed using the Prediction model Risk of Bias Assessment Tool in prediction model studies and Cochrane Risk of Bias and ROBINS‐I tool in intervention studies. We conducted meta‐analyses for intervention studies (RCTs only) when outcomes were comparable. Results: We included 19 studies on decision support tools for perioperative opioid management: seven development and one impact study on personalised prediction models and 11 intervention studies on nociception monitoring systems. All prediction model studies predicted postoperative opioid requirements, had a high risk of bias, limited external validation and poor overall performance (R 2 range: 0.100–0.313). None were clinically tested or provided advice on optimal opioid dosing. For intervention trials evaluating nociception monitoring systems, meta‐analyses showed no significant effect on pain, opioid use, or opioid‐related adverse events within 24 h after surgery. No studies tested risk stratified/individualised opioid treatment. Conclusion: No prediction model study provided concrete guidance for individualising systemic opioid treatment. Nociception monitor–guided opioid doses did not improve acute postoperative pain, opioid use or opioid‐related adverse events. Editorial Comment: This systematic review assessed if available tested prediction models for individual guiding of opioid analgesic dosing, including monitors designed to assess nociceptive signal influence on clinical status, were of benefit in clinical practice. Findings, for outcomes analgesic effect, opioid dosing, or adverse events related to opioids, none of the models or systems have been demonstrated to have cliear clinical utility for optimizing opioid dosing.


  • Minimal Important Difference for Rescue Opioid Consumption in Adults With Acute Pain: A Scoping Review

    by Atena Saito, Jens Laigaard, Pernille Bjersand Sunde, Caroline Folkersen, Ida Houtved Rasmussen, Selma Pedersen Kjartansdóttir, Ole Mathiesen, Anders Karlsen

    Background: The minimal important difference (MID) is established for pain intensity scores in acute pain management, but not for rescue opioid consumption. This scoping review aimed to estimate the MID in rescue opioid consumption for acute pain among adult patients in the postoperative and emergency settings. Methods: We searched MEDLINE, Embase, CENTRAL, clinicaltrials.gov and clinicaltrialsregister.eu for studies published in English from inception to May 2024. We included studies investigating the MID of rescue opioid consumption in adults with acute pain in the postoperative and emergency settings. Because limited studies explicitly investigated the MID, we also included studies assessing the dose–response relationship between opioid consumption and relevant anchors (e.g., pain intensity scores). The primary outcome was MID for 0–24 h rescue opioid consumption; secondary outcomes included longer postoperative periods. Results: We screened 11,748 citations and included 14 studies (8190 patients). Three studies explicitly evaluated MID for rescue opioid consumption. In the remaining 11 studies, we estimated the MID using a 10‐point difference (0–100 scale) in pain intensity score as an anchor. The anchor‐based estimates ranged from 2 to 5 mg IV morphine equivalents, varying by population, method and context. Conclusions: Based on the currently available evidence, we propose a provisional MID of 5 mg IV morphine equivalent in rescue opioid consumption for acute pain. This is lower than the value used in most sample size calculations. Significance Statement: These results can guide sample size calculations and support patient‐centered approaches in acute pain settings. Trial Registration: PROSPERO identifier: CRD42024547409


  • Open Access

    Chronic pain after primary total and medial unicompartmental knee arthroplasty for osteoarthritis: a Danish nationwide cross-sectional survey

    by Jens Laigaard, Saber M Aljuboori, Lone Nikolajsen, Ole Mathiesen, Troels H Lunn, Martin Lindberg-Larsen, Søren Overgaard

    Background and purpose: Contemporary data on the risk of chronic pain after total knee arthroplasty (TKA) and unicompartmental knee arthroplasty (UKA) is limited. Therefore, we aimed to investigate the incidence of chronic pain, pain characteristics, patterns of analgesic use, patient satisfaction, and willingness to undergo the same surgery again, 1 year after primary TKA and UKA for osteoarthritis.Methods: We conducted a nationwide online survey among unselected patients who underwent primary TKA or medial UKA for primary osteoarthritis in Denmark. At 1 year postoperatively, we assessed the incidence of moderate to severe pain (≥ 4 on the 0–10 numerical rating scale), frequency of pain, pain interference with everyday life, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain domain, the Douleur Neuropathique 4 interview (DN4i), use of analgesics, satisfaction, and willingness to undergo the same surgery again.Results: We sent survey invitations to 2,580 TKA patients and 1,007 UKA patients who underwent surgery in 2022. Of the 70% TKA respondents, 25% had moderate to severe chronic pain, 82% were satisfied/very satisfied with the result of surgery, and 86% indicated that they would choose to undergo surgery again. Of the 75% UKA respondents, 23% had moderate to severe chronic pain, 86% were satisfied/very satisfied, and 88% would undergo the same surgery again.Conclusion: In Denmark, 25% of TKA patients and 23% of medial UKA patients experienced moderate to severe knee pain after 1 year. These numbers were higher than most previous estimates. Most patients were satisfied with the result of surgery and would undergo the same surgery again.


  • Open Access

    Chronic Postsurgical Pain after Primary Total Hip Arthroplasty for Osteoarthritis: A Nationwide Cross-Sectional Survey Study

    by Jens Laigaard, Saber Muthanna Aljuboori, Lone Nikolajsen, Ole Mathiesen, Troels Haxholt Lunn, Søren Overgaard